IDEAYA Biosciences - IDYA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.17
  • Forecasted Upside: 10.61%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$30.89
▼ -0.37 (-1.18%)

This chart shows the closing price for IDYA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IDEAYA Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IDYA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IDYA

Analyst Price Target is $34.17
▲ +10.61% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is $34.17, with a high forecast of $44.00 and a low forecast of $24.00. The average price target represents a 10.61% upside from the last price of $30.89.

This chart shows the closing price for IDYA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in IDEAYA Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/17/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/14/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2023

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/6/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$36.00Low
11/30/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$35.00 ➝ $41.00Low
11/8/2023GuggenheimLower TargetBuy ➝ Buy$48.00 ➝ $44.00Low
11/8/2023WedbushReiterated RatingOutperform ➝ Outperform$43.00Low
10/24/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$32.00 ➝ $36.00Low
10/11/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$32.00Low
9/12/2023The Goldman Sachs GroupBoost TargetBuy ➝ Buy$31.00 ➝ $37.00Low
9/12/2023WedbushBoost TargetOutperform ➝ Outperform$40.00 ➝ $43.00Low
8/17/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$28.00 ➝ $32.00Low
8/11/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$30.00 ➝ $32.00Low
8/11/2023WedbushBoost TargetOutperform ➝ Outperform$35.00 ➝ $40.00Low
8/11/2023OppenheimerBoost TargetOutperform ➝ Outperform$30.00 ➝ $35.00Low
8/8/2023Leerink PartnrsReiterated RatingOutperformLow
8/8/2023SVB LeerinkInitiated CoverageOutperform$33.00Low
8/8/2023SVB SecuritiesInitiated CoverageOutperform$33.00Low
5/24/2023The Goldman Sachs GroupInitiated CoverageBuy$32.00Low
4/24/2023WedbushBoost Target$30.00 ➝ $35.00Low
4/24/2023OppenheimerBoost Target$26.00 ➝ $30.00Low
4/24/2023GuggenheimBoost Target$32.00 ➝ $40.00Low
4/24/2023Stifel NicolausUpgradeHold ➝ Buy$18.00 ➝ $24.00Low
3/23/2023Berenberg BankInitiated CoverageBuy$26.00Low
3/17/2023CitigroupBoost Target$26.00 ➝ $29.00Low
3/8/2023GuggenheimReiterated RatingBuy$32.00Low
3/8/2023Royal Bank of CanadaReiterated RatingOutperform$25.00Low
2/28/2023Royal Bank of CanadaInitiated CoverageOutperform$25.00Low
1/23/2023OppenheimerBoost Target$22.00 ➝ $26.00Low
12/28/2022Capital One FinancialInitiated CoverageOverweight$29.00Low
12/14/2022WedbushBoost Target$30.00Low
11/18/2022Robert W. BairdBoost TargetOutperform$18.00 ➝ $24.00Low
10/27/2022CitigroupInitiated CoverageBuy$26.00Low
9/13/2022GuggenheimBoost TargetBuy$20.00 ➝ $32.00Low
9/6/2022OppenheimerBoost Target$22.00Low
8/16/2022Robert W. BairdLower TargetOutperform$26.00 ➝ $18.00Low
8/16/2022OppenheimerLower TargetOutperform$25.00 ➝ $20.00Low
8/15/2022Stifel NicolausDowngradeBuy ➝ Hold$16.00 ➝ $13.00Low
7/18/2022OppenheimerReiterated RatingOutperform$25.00Low
5/17/2022Roth CapitalBoost Target$42.00 ➝ $46.00High
3/16/2022WedbushReiterated RatingOutperform$34.00Medium
3/10/2022Stifel NicolausUpgradeHold ➝ Buy$27.00 ➝ $20.00Low
12/8/2021Roth CapitalBoost TargetBuy ➝ Buy$38.00 ➝ $42.00High
9/22/2021Stifel NicolausInitiated CoverageHold$27.00High
8/11/2021HC WainwrightLower TargetBuy$34.00 ➝ $30.00Medium
5/11/2021HC WainwrightLower TargetBuy$35.00 ➝ $34.00High
4/22/2021Roth CapitalBoost TargetPositive ➝ Buy$31.00 ➝ $38.00Low
4/19/2021HC WainwrightBoost TargetPositive ➝ Buy$29.00 ➝ $35.00High
4/16/2021Roth CapitalBoost Target$23.00 ➝ $31.00Low
4/16/2021JPMorgan Chase & Co.Boost TargetOverweight$28.00 ➝ $34.00High
3/24/2021CitigroupBoost Target$20.00 ➝ $33.00Medium
3/15/2021WedbushBoost TargetOutperform$25.00 ➝ $32.00Low
3/11/2021GuggenheimInitiated CoverageBuy$32.00High
10/7/2020Northland SecuritiesReiterated RatingBuy$28.00High
10/6/2020WedbushInitiated CoverageOutperform$21.00High
9/28/2020Northland SecuritiesReiterated RatingBuy$28.00Medium
9/1/2020Northland SecuritiesInitiated CoverageOutperform$28.00High
7/13/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$28.00High
6/17/2020HC WainwrightBoost TargetBuy$13.00 ➝ $22.00High
6/16/2020OppenheimerBoost TargetOutperform$17.00 ➝ $25.00Low
6/8/2020HC WainwrightReiterated RatingBuy$13.00Low
5/12/2020OppenheimerInitiated CoverageBuy$17.00High
4/6/2020HC WainwrightInitiated CoverageBuy$13.00High
3/13/2020Roth CapitalInitiated CoverageBuy$12.00Medium
10/17/2019OppenheimerInitiated CoverageOutperform$17.00High
9/9/2019Robert W. BairdInitiated CoverageOutperform$30.00High
6/17/2019Jefferies Financial GroupInitiated CoverageBuy$14.00Low
6/17/2019CitigroupInitiated CoverageBuy$20.00Low
6/17/2019JPMorgan Chase & Co.Initiated CoverageNeutral$15.00Low
(Data available from 12/9/2018 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
5/13/2023
  • 8 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/12/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/11/2023
  • 7 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/10/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
10/10/2023
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/9/2023
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2023

Current Sentiment

  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
IDEAYA Biosciences logo
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $30.89
Low: $30.81
High: $32.12

50 Day Range

MA: $28.64
Low: $24.59
High: $32.41

52 Week Range

Now: $30.89
Low: $13.29
High: $33.24

Volume

895,697 shs

Average Volume

605,905 shs

Market Capitalization

$1.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of IDEAYA Biosciences?

The following Wall Street research analysts have issued reports on IDEAYA Biosciences in the last year: Berenberg Bank, Capital One Financial Co., Citigroup Inc., Guggenheim, JPMorgan Chase & Co., Leerink Partnrs, Oppenheimer Holdings Inc., Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., TheStreet, and Wedbush.
View the latest analyst ratings for IDYA.

What is the current price target for IDEAYA Biosciences?

12 Wall Street analysts have set twelve-month price targets for IDEAYA Biosciences in the last year. Their average twelve-month price target is $34.17, suggesting a possible upside of 10.6%. Guggenheim has the highest price target set, predicting IDYA will reach $44.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $24.00 for IDEAYA Biosciences in the next year.
View the latest price targets for IDYA.

What is the current consensus analyst rating for IDEAYA Biosciences?

IDEAYA Biosciences currently has 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IDYA will outperform the market and that investors should add to their positions of IDEAYA Biosciences.
View the latest ratings for IDYA.

What other companies compete with IDEAYA Biosciences?

How do I contact IDEAYA Biosciences' investor relations team?

IDEAYA Biosciences' physical mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (650) 443-6209 and its investor relations email address is [email protected]. The official website for IDEAYA Biosciences is www.ideayabio.com. Learn More about contacing IDEAYA Biosciences investor relations.